Evidence Updates

Peer-reviewed original paper | Advanced Science | Published 6 October 2026.

Exact tested intervention. Dry fruiting bodies of Ganoderma applanatum from Changbai Mountain, China; identity confirmed by the Chinese Academy of Sciences and voucher CCFM20221205 retained. Material underwent hot-water extraction, ethanol precipitation, DEAE anion-exchange chromatography and Superdex 75 size-exclusion chromatography. The principal fraction, GAP2, was the 0.2 mol/L NaCl-eluted fraction: a roughly 20.5 kDa linear beta-(1→3)-glucan, concentrated and lyophilized.

Dose, model and comparators. In the main screen, male C57BL/6j mice received 3% DSS plus crude polysaccharides (300 mg/kg by gavage) or GAP1–GAP4 (50 mg/kg by gavage); model controls received PBS or saline. Randomized groups began at n=10, with reported endpoint subsets commonly n=5–7. Further randomized experiments used germ-free mice, fecal microbiota transfer, filtered fecal metabolites, Phocaeicola vulgatus FTJS7K1, and GH16/fabB knockout strains.

Outcomes. GAP2 improved weight recovery, colon length, histology, mucin and tight-junction markers in DSS-treated mice. In germ-free mice, direct GAP1/GAP2 dosing was largely null; transfer of microbiota or filtered metabolites from treated donors restored effects. The authors link GAP2 fermentation by P. vulgatus to tridecylic acid production and Rho/CDC42-associated tight-junction signalling.

Design quality. Strengths include intervention fractionation, structural characterization, random allocation, blinded histology, germ-free transfer experiments and bacterial gene knockouts. Public Chinese research grants funded the work; the authors declared no conflicts.

Limits and bias. This remains a set of small animal and cell experiments using an acute chemical colitis model. No preregistration or power calculation is reported. The human datasets are observational and did not measure the proposed metabolite or host signalling. The Rho/CDC42 step was not tested with pathway blockade, and the Caco-2 methods section appears to label the fatty-acid exposure as myristic acid rather than tridecylic acid — a reporting inconsistency worth clarification.

Interpretation. This is a reasonably strong mechanistic advance for one purified fraction. It is not independent clinical replication and cannot be generalized to whole fruiting body, mycelium, crude extracts, other Ganoderma species or retail products.

Peer-reviewed original paper | Journal of Natural Medicines | Published 5 October 2026.

Reported intervention. A material called Ganoderma lucidum polysaccharide (GLP), given to randomized mice orally at 50 or 100 mg/kg/day or intraperitoneally at 50 mg/kg/day. The comparator injury model received isoproterenol 2 mg/kg/day subcutaneously for 11 days. AC16 human cardiomyocytes were pretreated with GLP before 40 micromol/L isoproterenol for 24 hours.

Why it was not promoted. The accessible report does not provide the fungal strain, source tissue, extraction process, formulation, degree of purification, main animal group size, sex or blinded outcome procedures. The abstract reports 0.25–1.00 micrograms/mL GLP in cells, while the supplementary figure reports 0.025–0.900 mg/mL — a large unit/range discrepancy. Outcomes (cardiac hypertrophy, histology, AST/LDH, energy metabolites and oxidative-stress markers) improved, but AMPK/PGC-1alpha/PPAR-alpha involvement is associative rather than established by perturbation.

Funding/conflicts. National Natural Science Foundation of China grants; authors declared no competing interests. Two companies were thanked for analytical-instrument access.

Commercial cordycepin of 98% HPLC purity — a purified molecule, not a Cordyceps militaris powder or extract; its manufacturing or fungal source was not specified. Fifty male BALB/c mice were randomized to control, intranasal LPS 3 mg/kg, or LPS followed 24 hours later by oral cordycepin at 20, 40 or 80 mg/kg for three days (n=10/group). There was no established-drug positive control. Parallel MH-S macrophage experiments used 0.1, 1 or 10 micromolar cordycepin after LPS, plus TAK1 knockdown and overexpression.

Cordycepin reduced histological lung injury and several inflammatory measures, generally with stronger effects at higher doses. The cellular perturbation experiments support dependence on TAK1-related signalling. Molecular docking alone does not demonstrate direct physical binding. This is a partial replication of earlier reports that cordycepin reduces LPS lung injury, while adding a proposed TAK1/MAPK/NF-kappaB mechanism.

Strengths include randomized allocation, three doses, n=10/group and genetic pathway perturbation. Limits include no formal prospective power calculation, no stated blinded outcome assessment, males only, a short artificial LPS model, fixed treatment order without cage rotation, and no positive comparator. Public Chinese grants funded the work; no conflicts were declared. The peer-reviewed study was newly indexed 26 September 2026.

A peer-reviewed study administered purified erinacine C at 100 mg/kg/day by gavage for 16 weeks to female APP/PS1 mice. The treatment group contained five mice, with four transgenic vehicle controls and four wild-type controls.

Behavioural and pathology signals were positive, but the extremely small groups, single dose, absent positive comparator and unreported blinding keep it below the high-quality tier. This is evidence about erinacine C, not lion's mane powder, fruiting bodies or mycelial supplements.

In a mouse 4T1 breast-tumour model, a preparation described as G. lucidum polysaccharides was tested alone and alongside low-dose gemcitabine. The polysaccharides alone altered immune measurements but did not significantly suppress tumour growth. Gemcitabine reduced tumour volume, while the combination produced greater inhibition and was associated with CD8-cell infiltration, inflammatory cytokines, microbiome changes and altered tryptophan metabolism.

Fungal strain, tissue, extraction method, molecular-weight specification, dose, route and group size are not adequately reported in the accessible indexed record. The microbiome and metabolic observations are predominantly associative; kynurenine was not measured despite the proposed IDO mechanism. Public sequence and metabolomics deposits improve transparency. Public Chinese research programmes funded the study and the authors declared no conflicts. The peer-reviewed study was published 19 September 2026.

Cut fungal material was reflux-extracted for two hours in 95% ethanol. The resulting extract was administered orally at approximately 95, 190 or 380 mg/kg in an ovariectomized-rat osteoporosis model; alendronate at 1.4 mg/kg/day served as a positive control.

The extract improved bone-mineral density and several micro-CT, trabecular and serum measures. Microbiome and phosphate-transporter changes were proposed as mechanisms, but microbiome profiling appears to have been confined to the high-dose group. Without microbiota-transfer, depletion or pathway-blockade experiments, causality is unestablished.

Strengths include multiple doses, a relevant positive control and structural bone measurements. Limitations include the preventive animal model, incomplete strain and chemical standardisation, selective microbiome analysis and an author affiliation with Mushroom Wisdom, Inc. The peer-reviewed study was published 21 September 2026.

Mice received G. lucidum spore oil at 800 mg/kg/day for 82 days. The study reported reductions in weight gain, fasting glucose, blood lipids and inflammatory markers, accompanied by microbiome, short-chain-fatty-acid and bile-acid changes. Fecal fermentation and HepG2 experiments explored possible microbiota-related mechanisms.

Only one dose was tested. Sample size, allocation, blinding, fungal strain, oil-production method and chemical standardisation were absent from the indexed abstract. Microbiome associations do not establish microbial causation, and this mouse dose cannot be translated directly into a human supplement claim. Funding came from Chinese public research programmes.

An authenticated maitake fruiting-body lot underwent repeated hot-water extraction, ethanol precipitation, ion-exchange purification and ultrafiltration. The nominally below-1-kDa PP-3 fraction had an apparent mass near 184 Da and 15.72% residual protein. It is more accurately described as an oligosaccharide-rich fraction than a conventional polysaccharide.

PP-3 gave the strongest tumour-cell and macrophage assay effects, but concentrations were high and the study lacked normal-cell controls, established anticancer comparators and endotoxin testing. For distribution work, chemically FITC/iodine-labelled material was given orally at 1 g/kg to ten rats; ten controls received saline. Calculated blood absorption peaked at 5.25% after two hours, with iodine signals mainly in liver and kidney.

ICP-MS detected iodine, not intact native PP-3, and labelling could alter distribution. The work demonstrates neither oral maitake absorption nor anticancer efficacy; it is instead a useful lesson in evidence ownership and chemically altered tracers.